Welcome to the e-CCO Library!

P452: Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatment
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. F. Guerra Veloz*1, F. Argüelles Arias1, R. Perea Amarillo1, L. Castro Laria1, M. B. Maldonado Pérez1, A. Benítez Roldán1, V. Merino2, G. Ramirez2, A. Vilches Arenas3, A. Caunedo Álvarez1

Created: Friday, 22 February 2019, 9:49 AM
P452: Silent anaemia predicts treatment change in patients with Crohn's disease in clinical remission
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Soufleris K., Kafalis N., Katsoula A., Chatzinakos G., Grammatikos N., Giouleme O.

Created: Wednesday, 20 February 2019, 10:36 AM
P452: Tofacitinib Effectiveness and Safety as Therapy for Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: McNally, M.(1);Keating, E.(2);Gray, E.(1);McCormick, E.(1);Carroll, A.(3);Palmer, C.(4);Kennedy, U.(1);McKiernan, S.(1);MacCarthy, F.(1);Dunne, C.(1);Hartery, K.(1);Egan, L.(2);Slattery, E.(2);Ryan, B.(3);McNamara, D.(3);O'Connor, A.(3);Breslin, N.(3);O'Donnell, S.(3);Cullen, G.(4);Mulcahy, H.(4);Sheridan, J.(4);Doherty, G.(4);Kevans, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P453 Comparison of therapeutic effects between groups of thiopurine alone and combination of thiopurine with 5-ASA after remission introduced by oral tacrolimus for patients with severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Sato1, K. Kojima2, R. Koshiba2, K. Fujimoto2, M. Kawai2, K. Kamikoduru2, Y. Yokoyama2, T. Miyazaki2, K. Watanabe1, N. Hida2, S. Nakamura2

Created: Thursday, 30 January 2020, 10:12 AM
P453: Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bernardo S., Fernandes S., Gonçalves A.R., Baldaia C., Valente A., Moura Santos P., Correia L., Velosa J.

Created: Wednesday, 20 February 2019, 10:36 AM
P453: Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Teich1, H. Gruemmer2, E. Joergensen3, T. Liceni4, W. Holtkamp-Endemann5, F. Cornillie6, S. Hohenberger7, T. Fischer*7

Created: Friday, 22 February 2019, 9:41 AM
P453: Insufficient vaccination and inadequate immunisation rates amongst Korean patients with inflammatory bowel diseases
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. H. Ryu1, H.-S. Lee2, B. D. Ye*3, N. Y. Kim4, E. J. Youn3, J. Y. Park3, E. Kang3, S. W. Hwang1, S. H. Park3, D.-H. Yang1, K.-J. Kim3, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang3

Created: Friday, 22 February 2019, 9:49 AM
P453: Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Law1, A. Narula2, A. Lightner3, J.-F. Colombel4, N.P. McKenna5, N. Narula2*

Created: Thursday, 21 February 2019, 9:14 AM
P453: The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zviaglova, M.(1)*;Knyazev, O.(1);Kagramanova, A.(1);Lischinskaya, A.(1);Podolskaya, D.(2);Nanaeva, B.(2);
Created: Friday, 14 July 2023, 11:05 AM
P453: The use of immunosuppresants is associated with high treatment persistence rates for infliximab and adalimumab as first or second line anti-TNF therapy in patients with inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Theodoraki, E.(1);Orfanoudaki, E.(1);Foteinogiannopoulou, K.(1);Drygiannakis, I.(1);Koutroubakis, I.E.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P453: Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Sharma, E.(1);Kotecha, J.(1);Akintimehin, A.(2);Ray, S.(1);Anderson, S.H.(1);Mawdsley, J.(1);Irving, P.M.(1);Samaan, M.A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P454 Serum oncostatin M predicts mucosal healing in Crohn’s disease patients treated with infliximab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Bertani1, L. Antonioli2, M. Fornili2, M. Fornai2, G. Tapete1, E. Albano1, G. Baiano Svizzero1, L. Ceccarelli3, M.G. Mumolo3, L. Baglietto2, S. Marchi1, C. Blandizzi2, F. Costa3

Created: Thursday, 30 January 2020, 10:12 AM
P454: Can calcineurin inhibitors induce a durable remission that is maintained with vedolizumab in IBD?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kassim O.1, Micic D.2, Christensen B.1, Pekow J.1, Sakuraba A.1, Dalal S.1, Rubin D.1, Cohen R.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P454: Combo-therapy in infliximab-resistant inflammatory bowel disease patients: data from a tertiary referral centre
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Renna*, G. Rizzuto, E. Orlando, M. Affronti, M. Cottone, A. Orlando

Created: Friday, 22 February 2019, 9:49 AM
P454: Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Yacoub1, N. Williet2, L. Pouillon1,3*, T. Di-Bernado2, M. De Carvalho Bittencourt4, S. Nancey5, A. Lopez1, S. Paul6, C. Zallot1, X. Roblin2, L. Peyrin-Biroulet1

Created: Thursday, 21 February 2019, 9:14 AM
P454: Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Saibeni, S.(1);Bezzio , C.(1);Armuzzi, A.(2);Daperno, M.(3);Zanetti, M.(4);Vernero, M.(5); Giorgetti, G.M.(6);
Created: Friday, 11 February 2022, 3:52 PM
P454: No increased postoperative risk of venous thromboembolism nor infectious complications after JAK inhibitor exposure in patients with ulcerative colitis undergoing colectomy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: De Greef, I.(1)*;Bislenghi, G.(2);Terrasson, I.(2);Sabino, J.(1);Ferrante, M.(1);D'Hoore, A.(2);Vermeire, S.(1);Verstockt, B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P454: Prediction of endoscopic activity in patients with Crohn’s disease: systematic review and external validation of published prediction models
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. C. Brand*1,2, S. G. Elias3, I. M. Minderhoud4, J. J. van der Veen1, F. Baert5, D. Laharie6, P. Bossuyt7, Y. Bouhnik8, A. Buisson9, G. Lambrecht10, E. Louis11, B. Pariente12, M. J. Pierik13, C. J. van der Woude14, G. R. D'Haens15, S. Vermeire16, B. Oldenburg1

Created: Friday, 22 February 2019, 9:41 AM
P454: Treatment with biologics improves disability from Inflammatory Bowel Disease in therapy responders
Year: 2021
Source: ECCO'21 Virtual
Authors: Castillo, G.(1);Sultan, K.(2);Kwah, J.(3);Chen, L.A.(4);Axelrad, J.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P455 Adherence to enteral nutrition therapy by adults with active Crohn’s disease is associated with conscientiousness personality trait
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Wall1, A. McCombie2, R. Mulder3, A. Day4, R. Gearry1

Created: Thursday, 30 January 2020, 10:12 AM